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Phenotypes Determined by Cluster Analysis and Their 
Survival in the Prospective European Scleroderma Trials 
and Research Cohort of Patients With Systemic Sclerosis
Vincent Sobanski,1  Jonathan Giovannelli,2 Yannick Allanore,3 Gabriela Riemekasten,4 Paolo Airò,5 
Serena Vettori,6 Franco Cozzi,7 Oliver Distler,8 Marco Matucci-Cerinic,9 Christopher Denton,10 David Launay,1 
Eric Hachulla,1 and the EUSTAR Collaborators
Objective. Systemic sclerosis (SSc) is a heterogeneous connective tissue disease that is typically subdivided 
into limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) depending on the extent of skin involve-
ment. This subclassification may not capture the entire variability of clinical phenotypes. The European Sclero-
derma Trials and Research (EUSTAR) database includes data on a prospective cohort of SSc patients from 122 
European referral centers. This study was undertaken to perform a cluster analysis of EUSTAR data to distinguish 
and characterize homogeneous phenotypes without any a priori assumptions, and to examine survival among the 
clusters obtained.
Methods. A total of 11,318 patients were registered in the EUSTAR database, and 6,927 were included in the 
study. Twenty- four clinical and serologic variables were used for clustering.
Results. Clustering analyses provided a first delineation of 2 clusters showing moderate stability. In an exploratory 
attempt, we further characterized 6 homogeneous groups that differed with regard to their clinical features, autoan-
tibody profile, and mortality. Some groups resembled usual dcSSc or lcSSc prototypes, but others exhibited unique 
features, such as a majority of lcSSc patients with a high rate of visceral damage and antitopoisomerase antibodies. 
Prognosis varied among groups and the presence of organ damage markedly impacted survival regardless of cuta-
neous involvement.
Conclusion. Our findings suggest that restricting subsets of SSc patients to only those based on cuta-
neous involvement may not capture the complete heterogeneity of the disease. Organ damage and antibody 
profile should be taken into consideration when individuating homogeneous groups of patients with a distinct 
 prognosis.
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INTRODUCTION
Systemic sclerosis (SSc) is a chronic disease that affects 
connective tissue and is characterized by vascular damage, auto-
immunity, and fibrosis. The European League Against Rheuma-
tism (EULAR) and the American College of Rheumatology (ACR) 
have recently developed new classification criteria for SSc (1). To 
date, the subclassification of SSc patients mainly relies on the 
cutaneous involvement subsets proposed by LeRoy et al in 1988 
(2–4). It separates patients into 2 main groups: diffuse cutane-
ous SSc (dcSSc) associated with early skin changes affecting the 
trunk and proximal limbs, and limited cutaneous SSc (lcSSc), in 
which skin fibrosis is limited to the hands, face, feet, and fore-
arms. Organ damage can vary between the 2 subsets, with an 
early and significant incidence of organ damage (lung fibrosis, 
gastrointestinal [GI] involvement, heart disease, and renal crisis) 
in dcSSc and pulmonary hypertension (PH) in lcSSc (4). The 2 
subsets also differ in autoantibody profile, with a high prevalence 
(70–80%) of anticentromere antibodies (ACAs) in lcSSc, and a 
predominant presence of antibodies against topoisomerase I 
(anti–topo I) in dcSSc (30%) compared to lcSSc in the study by 
LeRoy et al (4). In addition, mortality is higher in patients with 
dcSSc than in patients with lcSSc (5,6). Overall, previous studies 
suggest that lcSSc and dcSSc are 2 clearly differentiated pheno-
types with regard to clinical characteristics, serologic profiles, and 
 prognosis (7).
Yet, past and recent studies of large cohorts have challenged 
this distinction by highlighting an often- neglected heterogeneity 
among clinical subsets (8–12), as suggested by, for example, 
lcSSc patients with anti–topo I antibodies and severe interstitial 
lung disease (ILD). One method of dealing with heterogeneity is to 
conduct a cluster analysis in order to organize data from a hetero-
geneous population into a fairly small number of homogeneous 
groups. Cluster analysis has been applied to various conditions, 
such as gout (13), chronic heart failure (14), asthma (15), mixed 
connective tissue diseases (16), and antineutrophil cytoplasmic 
antibody–associated vasculitis (17). Cluster analyses have also 
been carried out in 2 SSc studies, to our knowledge (18,19). One 
of them included patients from the EULAR European Scleroderma 
Trials and Research (EUSTAR) cohort but was centered on cap-
illaroscopy patterns (18). Another recent study took into account 
a limited number of cluster variables and a limited number of 
patients (19). The aim of this study was to distinguish and charac-
terize homogeneous groups of SSc patients using cluster analysis 
within the large EUSTAR cohort, and analyze survival between the 
clusters obtained.
PATIENTS AND METHODS
Patient population. SSc patients were included in the 
prospective, open, multinational SSc EUSTAR cohort beginning in 
June 2004 (20–22). For the present study, the EUSTAR database 
was locked in April 2014. Eligible patients were age ≥18 years, 
fulfilled the ACR criteria for SSc (23), and had a calculable SSc dis-
ease duration, i.e., a date of disease onset (defined as the onset of 
the first non–Raynaud’s phenomenon symptom) and at least one 
date of study visit.
All patients agreed to participate in the EUSTAR cohort by 
signing informed consent forms approved by the local ethics 
committees. The study was conducted in accordance with the 
principles of the Declaration of Helsinki, local laws, and Guide-
lines for Good Clinical Practice (21,22). See Appendix A for a list 
of the EUSTAR Collaborators.
Definition and selection of variables. The EUSTAR 
database contains data on demographic characteristics, dis-
ease features, organ damage, laboratory parameters, capil-
laroscopy, echocardiography, pulmonary function tests (PFTs), 
and medication. In order to harmonize clinical practices and 
ensure reliable evaluation of parameters among centers, 
EU STAR arranges regular training courses and edits SSc man-
agement guidelines (24,25).
Autoantibodies were identified and characterized according 
to the local center’s guidelines (21,22). Clustering variables were 
selected in order to ensure a global phenotype of SSc patients 
by considering clinical relevance and representativeness of dis-
ease features, eliminating redundant variables providing analogous 
information, and dismissing variables with a high rate of missing 
values. We retained 24 variables, including symptoms or organ 
involvement observed at least once among visits (Raynaud’s phe-
nomenon, esophageal, stomach, and intestinal symptoms, digi-
tal ulcers, joint synovitis, joint contractures, tendon friction rubs, 
muscle weakness, muscle atrophy, arterial hypertension, palpita-
tions, and renal crisis), laboratory values (creatine kinase elevation, 
proteinuria, antinuclear antibody, ACA, and anti–topo I antibody 
positivity), results of other tests (restrictive defect on PFTs, lung 
fibrosis on plain radiography, conduction blocks, abnormal dias-
tolic function, suspected PH on cardiac echography), and the peak 
modified Rodnan skin thickness score (MRSS) observed during 
follow- up (Table 1 and Supplementary Figure 1,  available on the 
Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.com/
doi/10.1002/art.40906/ abstract). Each variable included for symp-
toms or organ involvement, laboratory values, and results of other 
tests was considered positive for a specific patient if “yes” was 
recorded at least once for that variable at any of the visits included.
Statistical analysis. Cluster analysis. Cluster analysis 
determines the distances between individuals using the com-
bined values of their measured features to obtain groups of 
individuals who have a greater resemblance to each other 
than to those in the other groups. Cluster analysis was car-
ried out by ascendant hierarchical clustering of the 24 selected 
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Table  1. Characteristics of the EUSTAR patients analyzed and not analyzed and characteristics of the patients in the present study by 
cutaneous subset*
EUSTAR population Study population
Patients analyzed 
(n = 6,927)
Patients not analyzed 
(n = 1,505) P† dcSSc lcSSc P†
% of patients – – – 42 58 –
Demographic 
characteristics
Sex, female 86 (6,924) 83 (1,505) <0.001 80 91 <0.001
Ethnicity <0.001 <0.001
White 95 (3,973) 87 (1,176) 92 97
Asian 3 (3,973) 11 (1,176) 5 2
Black 2 (3,973) 2 (1,176) 3 1
Age, mean ± SD years (n) 58.7 ± 13.2 (6,927) 56.3 ± 13.9 (1,505) <0.001 55.6 ± 13.0 60.9 ± 13.0 <0.001
Age at first non–Raynaud’s  
phenomenon symptom, 
mean ± SD years (n)
47.3 ± 13.3 (6,927) 47.6 ± 14.1 (1,505) 0.474 45.6 ± 13.2 48.5 ± 13.3 <0.001
Disease duration, mean ± 
SD years (n)‡
11.4 ± 8.1 (6,927) 8.7 ± 8.1 (1,505) <0.001 10.0 ± 7.4 12.4 ± 8.5 <0.001
Time from onset of  
Raynaud’s phenomenon 
to first non–Raynaud’s 
phenomenon symptom, 
mean ± SD years (n)
3.9 ± 8.0 (5,868) 3.4 ± 8.1 (1,351) <0.001 2.0 ± 5.6 5.2 ± 9.2 <0.001
Time from first non– 
Raynaud’s phenomenon 
symptom to EUSTAR 
enrollment, mean ± SD 
years (n)
9.4 ± 7.8 (4,875) 7.8 ± 7.8 (1,271) <0.001 8.0 ± 7.3 10.3 ± 8.1 <0.001
Time from EUSTAR enroll-
ment to last visit, mean 
± SD years (n)
2.6 ± 2.5 (4,875) 0.8 ± 1.7 (1,271) <0.001 2.7 ± 2.6 2.5 ± 2.5 0.031
Body mass index, mean ± 
SD kg/m2 (n)
23.6 ± 4.3 (2,483) 24.4 ± 4.8 (889) <0.001 22.9 ± 4.0 24.1 ± 4.4 <0.001
SSc characteristics
Autoantibody status
Antinuclear antibody 
positive§
96 (6,927) 94 (1,412) <0.001 97 96 0.400
Anticentromere antibody 
positive§
37 (6,927) 36 (1,264) 0.751 14 54 <0.001
Anti–topoisomerase I 
antibody positive§
39 (6,927) 36 (1,270) 0.028 61 23 <0.001
Anti–U1 RNP antibody 
positive
5 (4,054) 7 (807) 0.006 5 5 0.770
Anti- PM/Scl antibody 
positive
3 (3,335) 4 (648) 0.278 5 2 <0.001
Anti–RNA polymerase III 
antibody positive
4 (3,163) 6 (563) 0.025 6 3 <0.001
Cutaneous involvement
dcSSc 42 (6,913) 38 (1,437) 0.011 – – –
Peak MRSS value, mean 
± SD (n)§
12.0 ± 9.2 (6,927) 10.9 ± 9.7 (1,170) <0.001 18.3 ± 9.8 7.5 ± 5.2 <0.001
(Continued)
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EUSTAR population Study population
Patients analyzed 
(n = 6,927)
Patients not analyzed 
(n = 1,505) P† dcSSc lcSSc P†
Gastrointestinal involve-
ment¶
Esophageal symptoms§ 81 (6,927) 69 (1,498) <0.001 84 79 <0.001
Stomach symptoms§ 42 (6,927) 27 (1,491) <0.001 47 38 <0.001
Intestinal symptoms§ 43 (6,927) 33 (1,497) <0.001 44 42 0.027
Joint involvement
Joint contractures§ 48 (6,927) 35 (1,492) <0.001 64 36 <0.001
Joint synovitis§ 26 (6,927) 18 (1,496) <0.001 32 22 <0.001
Tendon friction rubs§ 17 (6,927) 8 (1,477) <0.001 28 9 <0.001
Vascular involvement
Raynaud’s phenome-
non§
98 (6,927) 97 (1,500) <0.001 98 98 0.340
History of or current 
digital ulcers§
49 (6,927) 35 (1,491) <0.001 58 42 <0.001
Muscular involvement
Muscle weakness§ 39 (6,927) 24 (1,488) <0.001 47 33 <0.001
Muscle atrophy§ 22 (6,927) 12 (1,484) <0.001 30 16 <0.001
CK elevation§ 13 (6,927) 13 (1,231) 0.711 18 9 <0.001
Cardiac involvement
Systemic arterial hyper-
tension§
34 (6,927) 27 (1,492) <0.001 33 35 0.150
Palpitations§ 39 (6,927) 26 (1,483) <0.001 41 38 0.014
Conduction blocks§ 22 (6,927) 14 (1,152) <0.001 24 20 <0.001
LVEF <50% 5 (4,239) 5 (879) 0.799 6 4 <0.001
Abnormal diastolic 
function§
33 (6,927) 22 (1,116) <0.001 34 33 0.588
Pericardial effusion 11 (4,442) 8 (920) 0.042 13 9 <0.001
Pulmonary hypertension
Pulmonary hypertension 
on echocardiography§
31 (6,927) 22 (1,173) <0.001 33 29 <0.001
Systolic PAP measured 
by echocardiography, 
mean ± SD mm Hg (n)
34.5 ± 15.3 (3,983) 34.2 ± 15.1 (727) 0.041 34.8 ± 16.4 34.2 ± 14.5 0.013
Interstitial lung disease
Lung fibrosis on plain 
radiography§
49 (6,927) 39 (1,033) <0.001 63 39 <0.001
Lung fibrosis on HRCT 57 (3,424) 53 (816) 0.023 68 48 <0.001
Restrictive defect on 
PFTs§
43 (6,927) 33 (1,083) <0.001 57 32 <0.001
FVC, mean ± SD %  
predicted (n)
89.3 ± 21.7 (4,349) 90.0 ± 21.8 (903) 0.437 81.4 ± 21.1 94.9 ± 20.3 <0.001
DLco, mean ± SD %  
predicted (n)
61.8 ± 20.1 (6,196) 66.1 ± 21.1 (1,026) <0.001 57.4 ± 19.9 64.9 ± 19.7 <0.001
6- minute walking 
distance, mean ± SD 
meters (n)
392 ± 134 (1,179) 411 ± 145 (338) 0.007 394 ± 137 391 ± 131 0.872
Table 1. (Cont’d)
(Continued)
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variables using Ward’s minimum variance method. Results 
were graphically represented in a dendrogram. We estimated 
the number of clusters using the visual distance criterion of the 
horizontal intersection at the highest dissimilarity level on the 
dendrogram (i.e., where the vertical branches were the lon-
gest). In an exploratory approach, we increased the number of 
clusters considered in the suboptimal visual distance criterion 
by cutting the dendrogram horizontally at the second highest 
level of dissimilarity (26).
Evaluation of clusterwise stability and reproducibility is a major 
issue in cluster analysis (27). To assess stability and reproducibility, 
we conducted 100 iterations of the clustering process (with the 
number of clusters in the primary analysis) in randomly selected 
subsets of up to 50% of the original data set, and estimated the 
clusterwise stability by computing the Jaccard coefficient (which is 
a measure of similarity between data sets) between every cluster 
of the primary analysis and the most comparable cluster retrieved 
in each iteration (27). A Jaccard similarity index of ≤0.5 indicates a 
weakly stable and reproducible cluster (28).
The main cluster analysis was carried out in patients without 
missing data for the 24 selected variables. In order to estimate 
the impact of late complications on the cluster analysis, we per-
formed a sensitivity analysis by selecting patients with a disease 
duration of >10 years (adequate time for the occurrence of organ 
damage). In order to study the possible impact of rare antibodies 
on the clustering process, we performed a second sensitivity anal-
ysis by adding in the clustering variables anti–RNA polymerase 
III, anti- PM/Scl, and anti–U1 RNP antibodies. Finally, a third sen-
sitivity analysis was conducted to evaluate the potential survival 
bias, and was restricted to patients with a disease duration at the 
enrollment visit of <5 years. The descriptive words used to refer 
to disease features or severity in the Results section (low/mild/
moderate/severe) were not used during the clustering process 
but were used to describe and interpret the groups of patients in 
accordance with established practice (13,14).
Survival analysis. Survival was assessed using disease 
duration (the time from disease onset to the most recent date 
data were obtained). We found that a high percentage (52%) 
of patients were lost to follow- up (i.e., data last obtained prior 
to January 2012), which was responsible for a significant over-
estimation of survival. Because we could not update data with 
actual vital status, we chose to exclude those patients from the 
survival analysis. A sensitivity analysis that included those pa-
tients was therefore performed. We also performed a sensitivity 
analysis using onset of Raynaud’s phenomenon as the definition 
of disease onset.
Survival rates were examined using several Cox proportional 
hazards models: unadjusted, adjusted for age at disease onset, 
adjusted for age at disease onset and sex, and adjusted for age 
at disease onset, sex, and immunosuppressive treatment. The 
proportional hazards assumption for Cox regression models 
was assessed by the graphical study of Schonfeld’s residues, 
EUSTAR population Study population
Patients analyzed 
(n = 6,927)
Patients not analyzed 
(n = 1,505) P† dcSSc lcSSc P†
Renal involvement
History of renal crisis§ 3 (6,927) 3 (1,497) 0.626 5 2 <0.001
Proteinuria§ 12 (6,927) 10 (1,308) 0.082 15 9 <0.001
Blood tests
CRP elevation 36 (4,736) 31 (1,100) <0.001 44 30 <0.001
Hypocomplementemia 11 (4,469) 10 (860) 0.409 12 11 0.504
Treatment
Past or current steroids 43 (4,647) 38 (1,081) 0.006 55 34 <0.001
Prednisone, mean ± SD 
mg/day (n)
4.4 ± 7.5 (4,644) 5.1 ± 9.7 (1,080) 0.081 6.0 ± 8.7 3.3 ± 6.1 <0.001
Past or current immuno-
suppressive drugs 
42 (4,631) 44 (1,085) 0.162 60 28 <0.001
* Except where indicated otherwise, values are the percent (number with data available). EUSTAR = European Scleroderma Trials and Research; 
dcSSc = diffuse cutaneous systemic sclerosis; lcSSc = limited cutaneous systemic sclerosis; MRSS = modified Rodnan skin thickness score; CK = 
creatine kinase; LVEF = left ventricular ejection fraction; PAP = pulmonary artery pressure; HRCT = high- resolution computed tomography; PFTs = 
pulmonary function tests; FVC = forced vital capacity; DLco = diffusing capacity for carbon monoxide; CRP = C- reactive protein. 
† By Student’s t- test for continuous variables and Fisher’s exact test for categorical variables. 
‡ Time between the first non–Raynaud’s phenomenon symptom and the last visit. 
§ Clustering variables. 
¶ Esophageal symptoms included dysphagia and/or reflux, stomach symptoms included early satiety and/or vomiting, and intestinal symptoms 
included diarrhea, bloating, and/or constipation. 
Table 1. (Cont’d)
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and the log linearity assumption for quantitative  predictors was 
assessed using cubic spline functions. Finally, we calculated the 
C- index for each Cox regression model (i.e., the estimation of 
the probability of concordance, which is equivalent to the area 
under the receiver operating characteristic curve for logistic 
regression models). Statistical analyses were carried out using 
Figure 1. A, Dendrogram of the 6,927 patients with systemic sclerosis (SSc) included in the cluster analysis. The length of the vertical lines 
represents the degree of similarity between patients. Patients were divided into 2 clusters (cluster A and B) and into 6 clusters (clusters 1–6). 
B, Heatmap showing the clinical characteristics in each cluster. dcSSc = diffuse cutaneous SSc; CK = creatine kinase; PH = pulmonary 
hypertension; CRP = C- reactive protein; ACA = anticentromere antibody; anti–topo I = anti–topoisomerase I.
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the “survival” and “fastcluster” packages in R software, version 
2.14 (29). P values less than 0.05 were considered significant.
RESULTS
Patient characteristics. A total of 11,318 patients 
(from 122 centers) were registered in the EUSTAR database 
as of April 2014, and 34,066 visits were recorded. Of these 
patients, 2,886 were excluded and 1,505 were not analyzed 
(due to ≥1 missing value for the variables used for clustering). 
Therefore 6,927 patients (from 120 centers) were incorporated 
in the cluster analysis (Supplementary Figure 2, available on the 
Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.
com/doi/10.1002/art.40906/ abstract). Compared to patients 
who were not included in the analysis, patients who were 
included were slightly older (mean ± SD age 58.7 ± 13.2 versus 
56.3 ± 13.9 years; P < 0.001), had a longer disease duration 
(mean ± SD 11.4 ± 8.1 versus 8.7 ± 8.1 years; P < 0.001), 
had a higher rate of dcSSc (42% versus 38%, P = 0.011), and 
had generally more severe disease as indicated by proportions 
of organ damage (Table 1). The median number of visits per 
patient was 3 (interquartile range 4).
Of the patients included, 42% had dcSSc and 58% had 
lcSSc. Patients with dcSSc were significantly younger than 
those with lcSSc, and had more severe disease. Of the patients 
with dcSSc, 14% had ACAs and 61% had anti–topo I antibod-
ies, and of the patients with lcSSc, 54% had ACAs and 23% had 
anti–topo I antibodies (Table 1). 
Primary cluster analysis. Clustering of individuals on 
the basis of the 24 selected variables yielded an optimal num-
ber of 2 clusters: cluster A and cluster B (Figure 1A). Jaccard 
indexes showed moderate stability: 0.64 for cluster A and 0.66 
for cluster B. The characteristics of the 2 clusters are summa-
rized in Table 2, Supplementary Table 1 (available on the Arthri-
tis & Rheumatology web site at http://onlin elibr ary.wiley.com/
doi/10.1002/art.40906/ abstract), and Figures 1B and 2. Con-
tingency tables (Supplementary Tables 2 and 3, available on the 
Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.
com/doi/10.1002/art.40906/ abstract) show the proportions of 
patients with ACAs and anti–topo I antibodies in the different 
subsets of SSc according to skin involvement (lcSSc or dcSSc).
Cluster A (n = 3,149; 45.5%). Cluster A contained 
 principally patients with lcSSc (81%). Less than a third of the 
patients in this cluster had severe organ damage (digital ul-
cers, intestinal symptoms, or muscle, joint, cardiac, or lung 
involvement). ACAs were present in 54% of the patients, and 
anti–topo I antibodies were present in 21%.
Cluster B (n = 3,778; 54.5%). Patients in cluster B were a lit-
tle younger than those in cluster A, with a younger age at disease 
onset. In cluster B, 61% of the patients had dcSSc. A majority 
of the patients presented with digital ulcers, joint  contractures, 
intestinal involvement, and ILD. The autoantibody profile was the 
opposite of that seen in cluster A; 54% of the patients were pos-
itive for anti–topo I antibodies and 22% were positive for ACAs.
Exploratory cluster analysis. In an exploratory attempt 
to decipher the heterogeneity of the disease, we then increased 
the number of clusters. Graphical observation of the dendrogram 
determined that a suboptimal number of clusters was 6  (Figure 1A). 
As a consequence, we observed a decrease in Jaccard coeffi-
cients (ranging from 0.32 to 0.68). The characteristics of clusters 
1–6 are summarized in Table 2, Figure 1B, and Figure 3.
Cluster 1 (n = 1,186; 17%). A majority of the patients in clus-
ter 1 (89%) had lcSSc, and most were female. They were older 
at disease onset, had a high prevalence of GI involvement, and 
had a low proportion of patients with ILD. Most of the patients in 
cluster 1 (79%) were ACA positive.
Cluster 2 (n = 720; 10%). Cluster 2 was composed mainly 
of lcSSc patients (71%), with increased frequencies of suspect-
ed PH by echocardiography (39%), ILD (85%), and restrictive 
defect (61%). Anti–topo I antibodies were present in 35% of the 
patients, and ACAs were present in 24%.
Cluster 3 (n = 1,243; 18%). Cluster 3 included mainly pa-
tients with lcSSc (79%) characterized by low prevalence of GI 
involvement and ILD. ACAs were twice as frequent as anti–topo 
I antibodies (48% versus 24%, respectively).
Cluster 4 (n = 1,673; 24%). Patients in cluster 4 were mainly 
lcSSc patients (63%) with severe disease as demonstrated by 
high proportions of cardiac and lung, muscular, joint, and GI in-
volvement and digital ulcers. Anti–topo I antibodies were present 
in 46% of the patients and ACAs in 29%.
Cluster 5 (n = 1,249; 18%). Cluster 5 consisted mainly of 
patients with dcSSc (72%), with a notable proportion of male 
patients (19%), and GI, joint, and cardiac disease and moderate 
lung involvement. Half of the patients in cluster 5 were anti–topo 
I antibody positive and 20% were ACA positive.
Cluster 6 (n = 856; 12%). Cluster 6 was characterized by 
the highest proportion of patients with dcSSc (92%) and men 
(21%), the highest mean peak MRSS (27.2), and severe disease 
as shown by high frequencies of GI, joint, muscular, renal, lung, 
and cardiac disease. Anti–topo I antibodies were present in 77% 
of the patients and ACAs in 12% of the patients.
Sensitivity cluster analyses. Three sensitivity clus-
ter analyses were conducted. The first included only patients 
with a disease duration of >10 years (Supplementary Table 4, 
available on the Arthritis & Rheumatology web site at http://
onlin elibr ary.wiley.com/doi/10.1002/art.40906/ abstract), the 
second included anti–U1 RNP, anti–RNA polymerase III, and 
anti- PM/Scl antibodies as clustering variables (Supplementary 
Table 5, available on the Arthritis & Rheumatology web site at 
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Table 2. Characteristics of the patients in the 2 and 6 clusters found in the cluster analysis (n = 6,927)*
2 clusters 6 clusters
Cluster A Cluster B Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 Cluster 6
Jaccard index 0.64 0.66 0.39 0.32 0.57 0.38 0.68 0.43
No. of patients 3,149 3,778 1,186 720 1,243 1,673 1,249 856
Demographic 
characteristics
Sex, female 90 84 94 88 88 88 81 79
Ethnicity
White 94 96 97 88 94 96 94 96
Asian 5 2 2 10 4 2 3 2
Black 2 2 1 2 2 2 3 2
Age, mean ± SD 
years
59.2 ± 13.3 58.2 ± 13.2 61.3 ± 12.9 60 ± 12.8 56.6 ± 13.5 61.2 ± 12.6 55.8 ± 13.2 55.9 ± 13.2
Age at first non- 
Raynaud’s symp-
tom, mean ± SD 
years
47.9 ± 13.3 46.7 ± 13.3 48.9 ± 13.1 48.3 ± 12.8 46.7 ± 13.6 48.1 ± 13.1 46 ± 13.4 45.1 ± 13.4
Disease duration, 
mean ± SD years†
11.3 ± 8.2 11.5 ± 8.1 12.4 ± 8.1 11.8 ± 8.3 9.9 ± 7.9 13.2 ± 8.4 9.8 ± 7.6 10.8 ± 7.5
Time from onset of 
Raynaud’s phe-
nomenon to first 
non–Raynaud’s 
phenomenon 
symptom, mean ± 
SD years
4.8 ± 8.7 3.1 ± 7.3 5.4 ± 8.7 4.4 ± 9.1 4.4 ± 8.5 3.9 ± 8.2 2.8 ± 6.6 2.2 ± 6.1
Time from first 
non–Raynaud’s 
phenomenon 
symptom to EU-
STAR enrollment, 
mean ± SD years
9.4 ± 7.9 9.3 ± 7.8 10.3 ± 7.9 9.8 ± 8.2 8.2 ± 7.4 10.5 ± 8.1 8.1 ± 7.4 8.6 ± 7.4
Time from EUSTAR 
enrollment to last 
visit, mean ± SD 
years
2.2 ± 2.3 2.8 ± 2.6 2.5 ± 2.3 2.3 ± 2.5 1.8 ± 2.2 3 ± 2.7 2.4 ± 2.5 2.9 ± 2.5
Body mass index, 
mean ± SD kg/m2
24.1 ± 4.3 23.2 ± 4.2 24.3 ± 4.4 24.5 ± 4.6 23.6 ± 4 23.6 ± 4.4 23.3 ± 3.9 22.1 ± 4.2
SSc characteristics
Autoantibody status
Antinuclear anti-
body positive‡
96 97 98 94 95 97 95 98
Anticentromere 
antibody posi-
tive‡
54 22 79 24 48 29 20 12
Anti–topoisomer-
ase I antibody 
positive‡
21 54 8 35 24 46 50 77
Anti–U1 RNP anti-
body positive
5 5 3 8 5 7 3 4
Anti- PM/Scl anti-
body positive
2 4 1 3 1 4 4 6
Anti–RNA poly-
merase III anti-
body positive
3 5 2 3 4 3 6 6
(Continued)
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2 clusters 6 clusters
Cluster A Cluster B Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 Cluster 6
Cutaneous involve-
ment
dcSSc 19 61 11 29 21 37 72 92
Peak MRSS, mean 
± SD‡
6.6 ± 4.3 16.5 ± 9.8 6.6 ± 4.2 7.2 ± 4.6 6.3 ± 4.1 9.2 ± 5.3 19 ± 6.7 27.2 ± 8.7
Gastrointestinal 
involvement§
Esophageal symp-
toms‡
73 88 88 76 58 91 79 95
Stomach symp-
toms‡
26 55 52 16 7 60 36 70
Intestinal symp-
toms‡
33 50 64 21 11 57 34 63
Joint involvement
Joint contractures‡ 24 67 29 17 23 65 55 91
Joint synovitis‡ 14 37 15 13 15 37 25 53
Tendon friction 
rubs‡
4 28 6 3 4 19 19 57
Vascular 
 involvement
Raynaud’s phe-
nomenon‡
98 99 99 98 97 99 98 99
History of or 
current digital 
ulcers‡
32 63 35 24 33 62 50 85
Muscular 
 involvement
Muscle weakness‡ 16 59 27 8 10 69 33 77
Muscle atrophy‡ 6 35 9 3 6 38 17 57
CK elevation‡ 6 18 7 7 5 17 13 26
Cardiac involvement
Systemic arterial 
hypertension‡
31 37 38 28 26 44 26 38
Palpitations‡ 25 51 38 32 9 64 28 57
Conduction 
blocks‡
12 30 16 14 6 39 16 34
LVEF <50% 3 7 3 3 2 6 5 10
Abnormal diastolic 
function‡
24 42 27 33 15 54 24 43
Pericardial effusion 7 14 7 11 4 15 9 18
Pulmonary 
 hypertension
Pulmonary hyper-
tension on echo-
cardiography‡
21 39 24 39 8 44 24 50
Systolic PAP 
measured by 
echocardiogra-
phy, mean ± SD 
mm Hg
32.5 ± 13.7 36 ± 16.2 33 ± 14.3 36.7 ± 14.1 29.4 ± 12 37.2 ± 14.6 32.4 ± 12 38.1 ± 22.1
Table 2. (Cont’d)
(Continued)
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http://onlin elibr ary.wiley.com/doi/10.1002/art.40906/ abstract), 
and the third included only patients with a disease duration of 
<5 years at the enrollment visit (Supplementary Table 6, avail-
able on the Arthritis & Rheumatology web site at http://onlin e 
libr ary.wiley.com/doi/10.1002/art.40906/ abstract). Results of 
the sensitivity analyses were similar to those of the main cluster 
analysis.
Survival analyses. Kaplan- Meier curves are shown in 
Figures 2 and 3 and Supplementary Figures 3 and 4 (available 
on the Arthritis & Rheumatology web site at http://onlin elibr ary.
wiley.com/doi/10.1002/art.40906/ abstract). Survival rates are 
presented in Supplementary Table 7 (available on the Arthri-
tis & Rheumatology web site at http://onlin elibr ary.wiley.com/
doi/10.1002/art.40906/ abstract), and the results of Cox regres-
sion analyses are shown in Table 3.
The risk of death was increased for patients with dcSSc 
compared to patients with lcSSc, with a hazard ratio (HR) of 
2.03 (95% confidence interval [95% CI] 1.61–2.56) in the most- 
adjusted model. An increased risk of death was also present in 
2 clusters 6 clusters
Cluster A Cluster B Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 Cluster 6
Interstitial  
lung disease
Lung fibrosis on 
plain radiogra-
phy‡
29 65 8 85 17 72 46 80
Lung fibrosis on 
HRCT
38 70 22 78 29 73 56 82
Restrictive defect 
on PFTs‡
24 58 13 61 14 60 42 77
FVC, mean ± SD % 
predicted
97.8 ± 19.3 82.7 ± 21.1 101.2 ± 17.4 86.7 ± 21.9 99.9 ± 17.7 84.4 ± 20.8 87.5 ± 19.8 72.8 ± 20.3
DLco, mean ± SD % 
predicted
68 ± 18.9 56.6 ± 19.7 69.8 ± 17.2 57.7 ± 19.3 72.3 ± 18 55.2 ± 18.8 62.5 ± 20.3 50.6 ± 18.1
6- minute walking 
distance, mean ± 
SD meters
411 ± 129 381 ± 136 400 ± 135 405 ± 130 427 ± 121 366 ± 133 418 ± 130 362 ± 138
Renal involvement
History of renal 
crisis‡
2 4 2 1 2 4 3 8
Proteinuria‡ 7 16 6 8 7 15 11 26
Blood tests
CRP elevation 24 45 25 29 20 43 36 62
Hypocomplemen-
temia
10 13 13 7 8 14 10 12
Treatment
Past or current 
steroids
27 55 22 45 24 57 44 65
Prednisone, mean 
± SD mg/day
2.8 ± 6.4 5.7 ± 7.9 2 ± 4.9 5.5 ± 9.3 2.3 ± 5.6 5.6 ± 7.6 4.6 ± 7.6 7.3 ± 8.8
Past or current 
immunosup-
pressive drugs
27 54 17 44 27 48 54 66
Mortality
Number of deaths 
per 1,000 
patient- years
10.3 22.6 7.5 17.3 9.7 19.1 20.8 31.9
* Except where indicated otherwise, values are the percent of patients. See Table 1 for definitions. 
† Time between the first non–Raynaud’s phenomenon symptom and the last visit. 
‡ Clustering variables. 
§ Esophageal symptoms included dysphagia and/or reflux, stomach symptoms included early satiety and/or vomiting, and intestinal symptoms 
included diarrhea, bloating, and/or constipation. 
Table 2. (Cont’d)
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cluster B compared to cluster A (HR 2.47 [95% CI 1.86–3.27]). 
When analyzing 6 clusters, we noticed a continuous increasing 
mortality from cluster 1 to cluster 6 in the most- adjusted model. 
The risk of death had a magnitude superior to those noted in the 
2 previous analyses (i.e., HR 6.14 [95% CI 3.81–9.89] for cluster 
6 compared to cluster 1). C- indexes were similar for the most- 
adjusted models: lcSSc versus dcSSc, cluster A versus cluster B, 
and for the 6 clusters (mean ± SEM 0.78 ± 0.02, 0.78 ± 0.02, and 
0.79 ± 0.02, respectively).
The sensitivity analysis taking into account patients who were 
lost to follow- up yielded comparable HRs when we examined sur-
vival in clusters A and B and clusters 1–6 (data not shown). We 
also performed a sensitivity analysis using the onset of Raynaud’s 
phenomenon as the date of disease onset (Supplementary Table 8, 
available on the Arthritis & Rheumatology web site at http://onlin elibr 
ary.wiley.com/doi/10.1002/art.40906/ abstract), which yielded similar 
results, albeit the number of patients with available data was lower.
DISCUSSION
This study aimed to distinguish homogeneous groups in 
a substantial population of ~7,000 SSc patients using a clus-
Figure 2. A, Main characteristics of the 2 clusters (cluster A and cluster B) of patients with systemic sclerosis (SSc). B, Left, Proportions of 
each cluster with the main clinical characteristics of diffuse cutaneous SSc (dcSSc), restrictive defect, and suspected pulmonary hypertension 
(PH) on echocardiography (echo). Right, Peak modified Rodnan skin thickness score (MRSS), mortality (per 1,000 patient- years [py]), and 
percentages of patients with anticentromere antibodies (ACAs) and anti–topoisomerase I (anti–topo I) antibodies in each cluster. C, Kaplan- 
Meier survival curves for the 2 clusters. D, Forest plot showing mortality hazard ratios and 95% confidence intervals for the 2 clusters. Broken 
line shows the hazard ratio for the reference group. Green symbols represent cluster A; orange symbols represent cluster B. DU = digital ulcer; 
ILD = interstitial lung disease.
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ter analysis. The study had 2 main findings. First, the optimal 
clustering divided patients into 2 distinct groups according to 
their clinical and serologic features and disease severity and 
prognosis; these 2 categories partially overlapped with the clas-
sifications dcSSc and lcSSc. Second, an exploratory analysis 
yielded 6 homogeneous subsets of individuals that broadly dif-
Figure 3. A, Main characteristics of the 6 clusters (clusters 1–6) of patients with systemic sclerosis (SSc). B, Left, Proportions of each cluster 
with the main clinical characteristics of diffuse cutaneous SSc (dcSSc), restrictive defect, and suspected pulmonary hypertension (PH) on 
echocardiography (echo). Right, Peak modified Rodnan skin thickness score (MRSS), mortality (per 1,000 patient- years [py]), and percentages 
of patients with anticentromere antibodies (ACAs) and anti–topoisomerase I (anti–topo I) antibodies in each cluster. C, Kaplan- Meier survival 
curves for the 6 clusters. D, Forest plot showing mortality hazard ratios and 95% confidence intervals for the 6 clusters. Broken line shows the 
hazard ratio for the reference group. Colors represent the different clusters as indicated in C. GI = gastrointestinal; ILD = interstitial lung disease; 
DLco = diffusing capacity for carbon monoxide; DU = digital ulcer.
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fered with regard to clinical features, autoantibody profiles, and 
survival.
The fact that 2 clusters were found could be considered a 
validation of the expected dichotomy between dcSSc and lcSSc. 
However, 19% of the patients in cluster A had dcSSc and 21% 
had anti–topo I antibodies. In cluster B, 39% of the patients had 
lcSSc and 22% had ACAs. No clear parallels between the severity 
of organ damage and the cutaneous extent of SSc were observed. 
This finding is consistent with the results of recent studies. For 
example, Nihtyanova et al demonstrated that the presence of sig-
nificant organ involvement was a strong predictor of prognosis, in 
both lcSSc and dcSSc, in a study of nearly 400 consecutive patients 
followed up for up to 15 years. Notably, survival curves were close 
for the 2 cutaneous subsets when organ damage was present (30). 
Taken together, these results suggest that, while there is consensus 
on the relevance and practicality of subdividing SSc into lcSSc and 
dcSSc (31), this binary classification may be too restrictive as a sep-
aration within a continuous spectrum of varying severity primarily 
driven by organ damage and subsequent prognosis (12).
In an exploratory attempt to study the heterogeneity of SSc 
more in depth, we found 6 additional clusters. Some of the 6 
clusters obtained were expected, since they were consistent with 
the historical descriptions of lcSSc and dcSSc. Indeed, cluster 1 
included patients with the classic presentation of lcSSc, i.e., older 
female patients with a low rate of severe organ damage, a high 
frequency of ACA positivity, and a generally favorable prognosis. 
Cluster 6 resembled the classic description of dcSSc, with a high 
rate of male patients, the highest frequency of anti–topo I anti-
body–positive patients, and a high rate of severe organ damage 
and poor prognosis. Intriguingly, we observed clusters of patients 
that seemed to be grouped together based on characteristics 
other than the degree of skin involvement. Cluster 2 was com-
posed principally of patients with lcSSc but with a rather high 
frequency of anti–topo I antibody–positivity and high rates of ILD 
and suspected PH. Of note, the prognosis for patients in clus-
ter 2 was significantly worse than that for patients in cluster 1. 
Similarly, cluster 4 consisted of predominantly patients with lcSSc, 
often with visceral complication. Cluster 5 comprised, for the most 
Table 3. Cox regression analyses*
Univariable analysis 
(n = 3,352)
Multivariable analysis
Adjusted for age at  
disease onset
(n = 3,352)
Adjusted for age at  
disease onset and sex 
(n = 3,352)
Adjusted for age at disease 
onset, sex, and immuno-
suppressive treatment 
(n = 2,887)
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Cutaneous 
involvement
lcSSc Reference Reference Reference Reference
dcSSc 1.90 (1.64–2.19) <0.001 2.39 (2.07–2.77) <0.001 2.14 (1.85–2.48) <0.001 2.03 (1.61–2.56) <0.001
C- index† 0.60 ± 0.01 0.73 ± 0.01 0.75 ± 0.01 0.78 ± 0.02
2 clusters
Cluster A Reference Reference Reference Reference
Cluster B 2.23 (1.88–2.65) <0.001 2.40 (2.02–2.85) <0.001 2.26 (1.91–2.69) <0.001 2.47 (1.86–3.27) <0.001
C- index† 0.59 ± 0.01 0.72 ± 0.01 0.74 ± 0.01 0.78 ± 0.02
6 clusters
Cluster 1 Reference Reference Reference Reference
Cluster 2 2.32 (1.62–3.31) <0.001 2.10 (1.46–3.00) <0.001 1.97 (1.38–2.82) <0.001 1.64 (0.88–3.03) 0.119
Cluster 3 1.30 (0.89–1.91) 0.172 1.63 (1.11–2.38) 0.012 1.62 (1.11–2.37)   0.013 1.97 (1.10–3.54) 0.023
Cluster 4 2.47 (1.86–3.27) <0.001 2.49 (1.88–3.30) <0.001 2.40 (1.81–3.19) <0.001 2.77 (1.74–4.39) <0.001
Cluster 5 3.03 (2.23–4.11) <0.001 3.77 (2.77–5.12) <0.001 3.37 (2.47–4.58) <0.001 3.22 (1.93–5.36) <0.001
Cluster 6 4.40 (3.30–5.87) <0.001 5.85 (4.38–7.81) <0.001 5.20 (3.89–6.95) <0.001 6.14 (3.81–9.89) <0.001
C- index† 0.63 ± 0.01 0.75 ± 0.01 0.76 ± 0.01 0.79 ± 0.02
* Disease onset was defined as the first non–Raynaud’s phenomenon symptom (see Supplementary Table 8, available on the Arthritis & Rheuma-
tology web site at http://onlin elibr ary.wiley.com/doi/10.1002/art.40906/ abstract, for sensitivity analysis using the onset of Raynaud’s phenome-
non as the definition of disease onset). HR = hazard ratio; 95% CI = 95% confidence interval; lcSSc = limited cutaneous systemic sclerosis; dcSSc 
= diffuse cutaneous systemic sclerosis. 
† The C- index was calculated for each Cox regression model, and corresponds to the estimation of the probability of concordance, equivalent 
to the area under the receiver operating characteristic curve for logistic regression models. A value of 1 indicates perfect agreement and 0.5 
indicates an agreement that is no better than chance. Values for the C- index are the mean ± SEM. 
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part, patients with dcSSc, but we noted lower frequencies of ILD 
and suspected PH in this group than in clusters 2, 4, or 6. These 
findings indicate that subclassifications established solely on the 
extent of skin involvement might not be entirely representative of 
the severity of organ damage and prognosis.
Furthermore, this work highlighted some groups of patients 
in which the classic relationships between lcSSc and ACAs 
and between dcSSc and anti–topo I antibodies were not obvi-
ous. For example, in cluster 2, 71% of the patients were classi-
fied as having lcSSc, although 85% had lung fibrosis. Moreover, 
we found a relatively small proportion of ACA- positive patients 
(24%) and a notable rate of anti–topo I antibody positivity (35%), 
which was unexpected in a group in which the majority of the 
patients had lcSSc. The prognosis for the patients in this group 
was worse than that for the patients in cluster 1, which included 
mainly patients with lcSSc and few with organ damage, which 
supports the findings of Nihtyanova et al (30). Likewise, a Cana-
dian Scleroderma Research Group study examined the clinical 
features and mortality of anti–topo I antibody–positive lcSSc and 
ACA- positive dcSSc patients. The autoantibody profile seemed 
to be more strongly associated with demographic characteristics 
and visceral damage than with the skin subgroup. Mortality was 
related to both skin and serologic profile (9). Kranenburg et al also 
demonstrated that lcSSc patients who were positive for anti–topo 
I antibodies contrasted with lcSSc patients who were negative for 
anti–topo I antibodies and dcSSc patients who were positive for 
anti–topo I antibodies in terms of survival and organ involvement 
(32). Taken together, those studies suggest that subclassification 
combining antibody profile and skin involvement might predict 
clinical outcomes more accurately than skin or serologic features 
alone (9,32).
The heterogeneity of SSc has been discussed over a long period, 
and many studies were published both before and after the work of 
LeRoy et al describing the limited and diffuse subsets (2–4,33,34). 
The significance of serologic profile has also been  highlighted by 
Patterson et al, who characterized 5 groups of patients with homo-
geneous clinical and organ involvement (11,12). Significant efforts 
to classify patients into subsets on the basis of common clinical 
phenotypes, rather than through a predetermined decision process, 
have proposed to classify individuals using changes in MRSS over 
time (34,35), changes in the forced vital capacity percent predicted 
value (36,37), or gene expression patterns in the skin (38,39). Each 
of these attempts has resulted in a small number of subsets that 
define the range of phenotypes captured by the stratification char-
acteristics (12). There is growing interest in a new subclassification 
of SSc that combines patterns of underlying pathogenesis, organ 
damage, and prognosis in order to personalize disease manage-
ment and ameliorate outcomes (12,31).
This study has strengths and limitations. The principal 
strengths are the number of patients included in this large, 
prospective, multicenter cohort, and the lack of any a priori 
assumptions. The main weakness is that several clinically rel-
evant variables were lacking or were disregarded due to the 
proportion of missing data being too high (e.g., autoanti bodies 
other than ACAs/anti–topo I antibodies, extent of ILD on 
high- resolution computed tomography [HRCT] scan, detailed 
skin involvement, and overlap syndromes). In addition, 1,505 
of 8,432 patients were excluded from the cluster analysis 
because of missing data for any of the selected clustering var-
iables. Since those excluded patients had slightly less severe 
disease than the included ones, it could affect the extrapola-
tion of our results. Imputation of missing data by model- based 
clustering was not performed because we could not assume 
that these data were missing at random (40,41). Moreover, 
several definitions of variables lacked precision (e.g., ILD was 
defined as lung fibrosis on radiography whereas HRCT scan is 
now widely used, and PH was defined as suspicion on echo-
cardiography without invasive confirmation).
We also acknowledge that a thorough analysis of treatment 
regimens was not possible due to missing data. Nevertheless, for 
a majority of the patients we were able to determine whether or not 
they had been taking an immunosuppressive drug. To account for 
the potential effect of these drugs on survival, survival analyses were 
adjusted for immunosuppressive treatment. A potentially important 
bias is the influence of disease duration on the clustering process, 
since the frequency of organ damage tends to increase as the dis-
order progresses. Also, disease duration at the enrollment visit was 
relatively long, raising the possibility that study results were influ-
enced by survival bias. Yet, the sensitivity analyses that included 
only patients with a long disease duration and those that included 
only patients with a short disease duration yielded similar results.
Another limitation is that a significant number of patients 
were excluded from the survival analysis because of loss to fol-
low- up. Nevertheless, this exclusion did not alter the survival 
differences between clusters in a sensitivity analysis. The pri-
mary aim of our study was not to assess the prognosis factors 
for survival in SSc, but to decipher the heterogeneity of SSc 
by a cluster analysis and describe the survival rate in the clus-
ters obtained, allowing us to validate this approach post hoc. 
In studies assessing the prognosis factors of survival, baseline 
data are most often used. In our study, we had to include 
follow- up data in order to identify the occurrence of organ 
involvement. Therefore, we considered an organ complication 
to be present if the corresponding variable was described as 
“positive” at least once among all the visits included for a spe-
cific patient. We did not describe the progression of organ 
involvement in the whole population or in the different clus-
ters because the limited number of follow- up visits precluded 
us from performing a precise temporal description. In the 
end, the weak reproducibility of the exploratory analysis with 
6 clusters precludes translating these results to a new sub-
classification (e.g., to allocate an individual to a designated 
group on the basis of their features). Moreover, previous stud-
ies have shown differences between distinct geographical 
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cohorts (42). Of note, 95% of the patients included in this 
study were white. It is likely that inclusion of a higher propor-
tion of Asian or black patients could have modified the results.
In conclusion, this study shows that SSc is a very hetero-
geneous condition. While there is consensus regarding the rele-
vance and practicality of the subclassification of SSc into lcSSc 
and dcSSc, this binary system might omit a wider spectrum of 
clinical phenotypes characterized not only by skin involvement but 
also by organ damage, serologic profile, and subsequent prog-
nosis. There is an increasing demand for a future SSc classifica-
tion that combines these different patterns, in order to personalize 
approaches to diagnosis and clinical management.
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